Riskpilot← Back to searchSign inGet full accessEDS Exosome Diagnostic Systems AB
ABBankruptOrg 5591124432Manufacture of instruments and appliances for measuring, testing and navigation · NACE 2651Est. 20170 employees
Revenue 2018
—
EBITDA margin
—
Equity ratio
—
Financial strength
Net profit 2018
—
0 employees
| Revenue | — | — |
| EBITDA | SEK 0 | — |
| Net profit | — | — |
| Total assets | — | — |
| Equity | — | — |
| Employees | 0 | — |
Legal name
EDS Exosome Diagnostic Systems AB
Org number
5591124432
Legal form
Aktiebolag
NACE code
2651 · Manufacture of instruments and appliances for measuring, testing and navigation
Founded
16 maj 2017
Share capital
SEK 0
Employees
0
VAT registered
No
Audit selected
No
Last report
2018-12-31
Financial year
January – December
Company purpose
Företaget utvecklar, producerar, marknadsför, licensierar och försäljer teknologi, komponenter, produkter och system för klinisk forskning och rutinklinisk kemisk analys inom områden såsom cancer och kroniska hjärnskador. Produktprogrammet baseras på analyter relaterade till exosomer, metastaserade celler och till dessa analoga biologiska strukturer, varvid systemstrukturen omfattar produkter såsom kemiska tester, instrument och programvara.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 |
|---|---|---|
| Revenue | 0 | — |
| Staff expenses | — | — |
| EBITDA | −28 | 0 |
| Depreciation & amort. | −0 | — |
| EBIT | −28 | 0 |
| Net financials | 6 | — |
| Profit before tax | −22 | 0 |
| Tax | −0 | — |
| Net profit | −22 | — |
| Item | 2017 | 2018 |
|---|---|---|
| Total assets | 230 | — |
| Equity | 228 | — |
| Long-term debt | 3 | — |
| Short-term debt | 0 | — |
| Total debt | 3 | — |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20172018
Equity ratio
0.0%
This company
38.2%
Market median
-100% vs market
20172018
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20172018
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20172018
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20172018
Debt / equity
-1.00×
This company
0.62×
Market median
+261% vs market
20172018
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-05-01 – 2017-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
HG Chief Executive Officer | Chief Executive Officer | 2021 |
MC | Audit | 2021 |
| Former (1) | ||
MC Auditor Substitute | Auditor Substitute | 2021 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2021 | |
| Board of Directors | 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of EDS Exosome Diagnostic Systems AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hans Gunnar Hendmont | Chief Executive Officer | 0 companies |
| Malin Camilla Nilsson | Auditor Substitute | 0 companies |
| Malin Christina Evesäter | Audit | 0 companies |
| Lars Olof Artur Hansson | Chairman | 0 companies |
| Teresa Maria Uhrdin | Board of Directors | 0 companies |